Covered recipient · General Payments record
JAMES JAY KEMPINERS
Allopathic & Osteopathic Physicians Otolaryngology
General Payments · PY2018–2024
$9,141.34
- Reported across 139 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $369.21 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| OptiNose US, Inc. | $114.04 | 5 |
| GENZYME CORPORATION | $90.35 | 3 |
| Smith & Nephew, Inc. | $50.18 | 2 |
| GlaxoSmithKline, LLC. | $41.52 | 2 |
| Medtronic, Inc. | $33.06 | 2 |
| BAXTER HEALTHCARE | $20.73 | 1 |
| Regeneron Healthcare Solutions, Inc. | $19.33 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Baxter Healthcare | $20.73 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120629279 | CMS |
| GENZYME CORPORATION | $35.43 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139634315 | CMS |
| GENZYME CORPORATION | $15.93 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139634383 | CMS |
| GENZYME CORPORATION | $38.99 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139634537 | CMS |
| GlaxoSmithKline, LLC. | $20.01 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115783082 | CMS |
| GlaxoSmithKline, LLC. | $21.51 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116251904 | CMS |
| Medtronic, Inc. | $18.13 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119394862 | CMS |
| Medtronic, Inc. | $14.93 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119394864 | CMS |
| Optinose US, Inc. | $17.07 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142177084 | CMS |
| Optinose US, Inc. | $24.53 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142177136 | CMS |
| Optinose US, Inc. | $23.80 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142177160 | CMS |
| Optinose US, Inc. | $19.65 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142177178 | CMS |
| Optinose US, Inc. | $28.99 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142177194 | CMS |
| Regeneron Healthcare Solutions, Inc. | $19.33 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114084648 | CMS |
| Smith+Nephew, Inc. | $28.59 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149584361 | CMS |
| Smith+Nephew, Inc. | $21.59 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149584359 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.